Riechardt Aline I

Riechardt Aline I, Stroux Andrea, Seibel Ira, Heufelder Jens, Zeitz Oliver, Böhmer Dirk et al.

This study found that for choroidal melanoma proton therapy, the radiation dose to the optic disc, not the irradiated optic nerve length, is the primary predictor for secondary glaucoma and other severe ocular complications.

Seibel Ira, Riechardt Aline I, Erb-Eigner Katharina, Böker Alexander, Cordini Dino, Heufelder Jens et al.

Proton beam therapy for uveal melanoma with posterior extraocular extension, including optic nerve invasion, showed no local recurrences over long-term follow-up. This suggests it's a safe and effective treatment option.

Riechardt Aline I, Pilger Daniel, Cordini Dino, Seibel Ira, Gundlach Enken, Hager Annette et al.

This study found that after proton beam therapy for choroidal melanoma, tumor height, ciliary body radiation dose, optic nerve irradiation, and diabetes mellitus are independent risk factors for neovascular glaucoma.

Seibel Ira, Riechardt Aline I, Heufelder Jens, Cordini Dino, Joussen Antonia M

This study found adjuvant endoresection or endodrainage after proton therapy for uveal melanoma reduces enucleation, radiation retinopathy, and neovascular glaucoma, improving globe preservation.

Riechardt Aline I, Cordini Dino, Rehak Matus, Hager Annette, Seibel Ira, Böker Alexander et al.

Trabeculectomy effectively lowered IOP in glaucoma patients after proton beam therapy for uveal melanoma, reducing medication. However, secondary interventions and metastasis risk require careful patient selection and tumor control.